Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro

被引:31
作者
An, Ran [1 ]
Hagiya, Yuichiro [1 ]
Tamura, Ai [1 ]
Li, Shanshan [1 ]
Saito, Hikaru [1 ]
Tokushima, Daisuke [2 ]
Ishikawa, Toshihisa [1 ]
机构
[1] Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan
[2] NEC Corp Ltd, Tokyo 1088001, Japan
关键词
ABCG2 (BCRP/MXR); cyclin-dependent kinase inhibitor; pheophorbide a; phototoxicity; porphyrin; BINDING CASSETTE ABC; MULTIDRUG-RESISTANCE; GENETIC POLYMORPHISMS; IMATINIB MESYLATE; CANCER CELLS; PROTEIN; EXPRESSION; DRUGS; DEATH;
D O I
10.1007/s11095-008-9738-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The physiological importance of the human ATP-binding cassette (ABC) transporter ABCG2 has been recognized with regard to porphyrin-mediated photosensitivity. Functional impairment owing to inhibition of ABCG2 by drugs or its genetic polymorphisms may lead to the disruption of porphyrin homeostasis, which in turn causes cellular toxicity. Materials and Methods. We evaluated the impact on photosensitivity of the inhibition by cyclin-dependent kinase (CDK) inhibitors of ABCG2 function. For this purpose, we established new methods for photosensitivity assays by using Flp-In-293 cells and plasma membrane vesicles prepared from Sf9 insect cells. With the new methods, we subsequently tested CDK inhibitors, i.e., purvalanol A, WHI-P180, bohemine, roscovitine, and olomoucine. Results. Among CDK inhibitors tested, purvalanol A was found to be the most potent inhibitor (IC50=3.5 mu M) for ABCG2-mediated hematoporphyrin transport. At a concentration of 2.5 mu M, it evoked the photosensitivity of ABCG2-expressing Flp-In-293 cells treated with pheophorbide a. WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. In contrast, the phototoxicity of bohemine, roscovitine, and olomoucine were minimal in our assay system. Conclusions. It is suggested that the planar structure is an important factor for interactions with the active site of ABCG2. The present study provides a new approach to studying drug-induced phototoxicity in vitro.
引用
收藏
页码:449 / 458
页数:10
相关论文
共 29 条
[11]   The role of transporters in cellular heme and porphyrin homeostasis [J].
Krishnamurthy, Partha ;
Xie, Tao ;
Schuetz, John D. .
PHARMACOLOGY & THERAPEUTICS, 2007, 114 (03) :345-358
[12]   Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1 [J].
MacCallum, DE ;
Melville, J ;
Frame, S ;
Watt, K ;
Anderson, S ;
Gianella-Borradori, A ;
Lane, DP ;
Green, SR .
CANCER RESEARCH, 2005, 65 (12) :5399-5407
[13]  
Maliepaard M, 1999, CANCER RES, V59, P4559
[14]  
Miyake K, 1999, CANCER RES, V59, P8
[15]   Protein kinase inhibitors: Insights into drug design from structure [J].
Noble, MEM ;
Endicott, JA ;
Johnson, LN .
SCIENCE, 2004, 303 (5665) :1800-1805
[16]   Cyclin dependent kinases and cell cycle control [J].
Nurse, PM .
BIOSCIENCE REPORTS, 2002, 22 (5-6) :487-499
[17]   High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter [J].
Özvegy-Laczka, C ;
Hegedus, T ;
Várady, G ;
Ujhelly, O ;
Schuetz, JD ;
Váradi, A ;
Kéri, G ;
Orfi, L ;
Német, K ;
Sarkadi, B .
MOLECULAR PHARMACOLOGY, 2004, 65 (06) :1485-1495
[18]   Expression of cell-cycle regulators p27(Kip1) and cyclin E, alone and in combination, correlate with survival in young breast cancer patients [J].
Porter, PL ;
Malone, KE ;
Heagerty, PJ ;
Alexander, GM ;
Gatti, LA ;
Firpo, EJ ;
Daling, JR ;
Roberts, JM .
NATURE MEDICINE, 1997, 3 (02) :222-225
[19]   Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitroxantrone-selected cell lines [J].
Ross, DD ;
Yang, WD ;
Abruzzo, LV ;
Dalton, WS ;
Schneider, E ;
Lage, H ;
Dietel, M ;
Greenberger, L ;
Cole, SPC ;
Doyle, LA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05) :429-433
[20]   Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate [J].
Rousselot, P ;
Larghero, J ;
Raffoux, E ;
Calvo, F ;
Tulliez, M ;
Giraudier, S ;
Rybojad, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :1091-1092